Literature DB >> 35471671

The potential roles of amino acids and their major derivatives in the management of multiple sclerosis.

Somayeh Pashaei1, Reza Yarani2,3, Pantea Mohammadi4, Mohammad Sajad Emami Aleagha5.   

Abstract

Recently, we reviewed the important role of carbohydrates and lipids metabolism in different clinical aspects of multiple sclerosis (MS) disease. In the current paper, we aimed to review the contribution of amino acids and their major derivatives to different clinical outcomes of the disease, including etiology, pathogenesis, diagnosis, prognosis, and treatment. In this line, Thr (threonine), Phe (phenylalanine), Glu (glutamate), Trp (tryptophan), and Sero (serotonin) are the main examples of biomolecules that have been suggested for MS therapy. It has been concluded that different amino acids and their derivatives might be considered prominent tools for the clinical management of MS disease.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Entities:  

Keywords:  Amino acids; Metabolic pathways; Multiple sclerosis

Mesh:

Substances:

Year:  2022        PMID: 35471671     DOI: 10.1007/s00726-022-03162-4

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  115 in total

1.  Cerebrospinal fluid lactate and glutamine are reduced in multiple sclerosis.

Authors:  J Aasly; M Gårseth; U Sonnewald; J A Zwart; L R White; G Unsgård
Journal:  Acta Neurol Scand       Date:  1997-01       Impact factor: 3.209

2.  Changes in neurotransmitters in multiple sclerosis.

Authors:  V P Barkhatova; I A Zavalishin; L Sh Askarova; V Kh Shavratskii; E G Demina
Journal:  Neurosci Behav Physiol       Date:  1998 Jul-Aug

Review 3.  Amino acid disorders.

Authors:  Ermal Aliu; Shibani Kanungo; Georgianne L Arnold
Journal:  Ann Transl Med       Date:  2018-12

4.  Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels.

Authors:  Vittorio Calabrese; Giovanni Scapagnini; Agrippino Ravagna; Rita Bella; Roberta Foresti; Timothy E Bates; Anna-Maria Giuffrida Stella; Giovanni Pennisi
Journal:  J Neurosci Res       Date:  2002-11-15       Impact factor: 4.164

5.  Relationship between genetic polymorphisms MTHFR (C677T, A1298C), MTR (A2756G) and MTRR (A66G) genes and multiple sclerosis: a case-control study.

Authors:  Suat Cakina; Ozgul Ocak; Adile Ozkan; Selma Yucel; Handan Isın Ozısık Karaman
Journal:  Folia Neuropathol       Date:  2019       Impact factor: 2.038

6.  The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.

Authors:  Narjes Babchia; Armelle Calipel; Frédéric Mouriaux; Anne-Marie Faussat; Frédéric Mascarelli
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-06       Impact factor: 4.799

7.  Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms.

Authors:  Shahin Aeinehband; Philip Brenner; Sara Ståhl; Maria Bhat; Mark D Fidock; Mohsen Khademi; Tomas Olsson; Göran Engberg; Jussi Jokinen; Sophie Erhardt; Fredrik Piehl
Journal:  Brain Behav Immun       Date:  2015-07-17       Impact factor: 7.217

8.  Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis.

Authors:  Sergio E Baranzini; Radhika Srinivasan; Pouya Khankhanian; Darin T Okuda; Sarah J Nelson; Paul M Matthews; Stephen L Hauser; Jorge R Oksenberg; Daniel Pelletier
Journal:  Brain       Date:  2010-09       Impact factor: 13.501

Review 9.  Human surrogate models of histaminergic and non-histaminergic itch.

Authors:  Hjalte H Andersen; Jesper Elberling; Lars Arendt-Nielsen
Journal:  Acta Derm Venereol       Date:  2015-09       Impact factor: 4.437

10.  Reduced GABA levels correlate with cognitive impairment in patients with relapsing-remitting multiple sclerosis.

Authors:  Guanmei Cao; Richard A E Edden; Fei Gao; Hao Li; Tao Gong; Weibo Chen; Xiaohui Liu; Guangbin Wang; Bin Zhao
Journal:  Eur Radiol       Date:  2017-10-06       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.